Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 07/27 03:20:46 pm
4659 GBp   +0.44%
10:01a ASTRAZENECA : Notice of Results
07/26 Takeda sets bidding deadline for chemical firm stake, CVC and Car..
07/25DJASTRAZENECA : 2Q 2016 -- Forecast
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
10:01a ASTRAZENECA : Notice of Results
07/26 Takeda sets bidding deadline for chemical firm stake, CVC and Carlyle may bid..
07/25DJASTRAZENECA : 2Q 2016 -- Forecast
07/20 ASTRAZENECA : Senators Collins, McCaskill Seek More Information on AstraZeneca's..
07/20 ASTRAZENECA : McCaskill Requests Information from AstraZeneca on Popular Drug Cr..
07/19DJValeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19DJASTRAZENECA : Gets EU Approval for Qtern to Treat Type 2 Diabetes
07/19 ASTRAZENECA : QTERN (saxa/dapa) EU approved for type-2 diabetes
07/19 ASTRAZENECA : Qtern Gets European Approval For Type 2 Diabetes
07/18 ASTRAZENECA : TAGRISSO® (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line..
More news
Sector news : Pharmaceuticals - NEC
03:02pDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- 2nd Update
02:33pDJGLAXOSMITHKLINE : Glaxo Swings to Loss on Write-Down But Core Earnings, Revenue ..
02:06pDJELI LILLY : CEO to Retire
02:06pDJGLAXOSMITHKLINE : Swings to Loss
02:02pDJELI LILLY : CEO Lechleiter to Retire, Ricks to Replace Him
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/26 FibroGen earns $10M milestone on start of late-stage roxadustat studies in Ja..
07/26 Generics Keeping The Pressure On Big Pharma
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 For The Real Relypsa Puzzle Look Beyond The Takeover
07/22 BIOTECH FORUM DAILY DIGEST : Relypsa Gets Bought Out, Biogen's Big Beat, Biotech..
Advertisement
Financials ($)
Sales 2016 23 028 M
EBIT 2016 5 432 M
Net income 2016 2 528 M
Debt 2016 10 898 M
Yield 2016 4,57%
P/E ratio 2016 29,30
P/E ratio 2017 27,74
EV / Sales 2016 3,82x
EV / Sales 2017 3,88x
Capitalization 77 078 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 68,0 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Edward Bradley Senior VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.48%77 078
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results